Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

TBPH holding history

Theravance Biopharma, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TBPH overviewAll 13F holders of TBPHFull Q2 2026 holdings

Shares (Q2 2026)
488,309
Value
$8.30M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of TBPH by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026488,309$8.30M<0.1%−275,796−36.1%ReducedHolders
Q1 2026764,105$12.4M<0.1%+193,680+34.0%AddedHolders
Q4 2025570,425$10.7M<0.1%+56,255+10.9%AddedHolders
Q3 2025514,170$7.51M<0.1%+117,037+29.5%AddedHolders
Q2 2025397,133$4.38M<0.1%−20,488−4.9%ReducedHolders
Q1 2025417,621$3.73M<0.1%+243,376+139.7%AddedHolders
Q4 2024174,245$1.64M<0.1%+143,488+466.5%AddedHolders
Q3 202430,757$247.9K<0.1%−3,015−8.9%ReducedHolders
Q2 202433,772$286.4K<0.1%−25,317−42.8%ReducedHolders
Q1 202459,089$530.0K<0.1%−11,917−16.8%ReducedHolders
Q4 202371,006$798.1K<0.1%+17,288+32.2%AddedHolders
Q3 202353,718$463.6K<0.1%+11,007+25.8%AddedHolders
Q2 202342,711$442.1K<0.1%+15,987+59.8%AddedHolders
Q1 202326,724$290.0K<0.1%+18,068+208.7%AddedHolders
Q4 20228,656$97.1K<0.1%+8,556+8,556.0%AddedHolders
Q3 2022100$1.00K<0.1%−193−65.9%ReducedHolders
Q2 2022293$2.00K<0.1%−3,256−91.7%ReducedHolders
Q1 20223,549$34.0K<0.1%+1,101+45.0%AddedHolders
Q4 20212,448$27.0K<0.1%+1,683+220.0%AddedHolders
Q3 2021765$6.00K<0.1%+665+665.0%AddedHolders
Q2 2021100$1.00K<0.1%−218,938−100.0%ReducedHolders
Q1 2021219,038$4.47M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.